Ewofex

Quick links to important sections

Ewofex

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ewofex

Quick Facts

Property Description
Active ingredient Fexofenadine hydrochloride
Form Oral tablets, oral suspension
Pharmacological class Antihistamine (Second-Generation)
Origin Synthetic, active metabolite

What Type of Medicine is Ewofex (Fexofenadine)?

Ewofex is a medicinal product containing the active ingredient fexofenadine hydrochloride, classified as a second-generation antihistamine intended for oral administration. Fexofenadine is a synthetic compound that functions as a pharmacologically active metabolite of the precursor drug, terfenadine. It belongs to the pharmacological class of selective peripheral H1 receptor antagonists, a definition based on its targeted action. The medicine is supplied in various dosage forms, including traditional film-coated tablets and liquid oral suspension, offering options for patient administration preferences.

Fexofenadine's designation as a second-generation compound represents its principal differentiation. This structure is specifically designed to achieve minimal blood-brain barrier crossing, which is the mechanism responsible for its non-sedating classification. Fexofenadine does not readily penetrate the central nervous system, unlike older agents. This property means patients can expect relief from allergy symptoms without typically experiencing the sedation associated with first-generation products.


What is the General Purpose of This Antihistamine?

The general purpose of Fexofenadine is to provide sustained systemic relief by managing the physical manifestations of allergic reactions. It achieves this by performing a precise histamine blockade at key cellular sites. The drug works by selectively occupying the body’s H1 receptors—sites where histamine, the primary chemical released during an allergy attack, would normally attach.

By acting as an antagonist at these peripheral receptors, Fexofenadine interrupts the cascade of events that leads to discomfort. Its core benefit is the management of general allergy discomforts, including sneezing, itchy or watery eyes, and runny nose, often encountered during a seasonal allergy flare-up. Fexofenadine is used to relieve symptoms linked to various allergic conditions. The drug is an option for providing general relief from the common signs of an allergic response. The ultimate aim of this targeted action is to mute the body’s exaggerated response to allergens, thereby supporting patients in maintaining normal daily function.

What side effects are possible with Ewofex?

Possible Side Effects and Safety Information

The safety profile for Ewofex (fexofenadine) is documented by health authorities based on clinical trial data and post-marketing surveillance. Adverse reactions are formally classified by the frequency observed. Reactions categorized as Common (affecting 1% to 10% of patients) primarily involve the Nervous System and Gastrointestinal domains, including headache, dizziness, drowsiness, and nausea.

Reactions reported at a lower incidence are classified as Uncommon, notably fatigue. Other events, such as palpitations, insomnia, nervousness, and diarrhea, have been reported in post-marketing experience with a Not Known frequency, meaning their incidence cannot be precisely estimated from available data.

The regulatory labeling documents potential serious adverse reactions primarily centered on systemic hypersensitivity events. These rare but clinically significant events include Systemic Anaphylaxis and Angioedema (swelling beneath the skin), which are manifestations requiring urgent medical observation.

Specific safety considerations are noted for certain populations. Caution is formally advised for administration to older adults and individuals with renal or hepatic impairment due to altered drug clearance or limited clinical data in these groups. Furthermore, the medicine is contraindicated in patients with known hypersensitivity to the active ingredient. Official documents also note that co-administration with aluminum or magnesium-containing antacids and certain fruit juices may reduce the drug's overall absorption.

Overdose and Emergency Response

The official regulatory documentation for fexofenadine describes specific clinical manifestations that may occur following an overdose. The documented signs commonly include neurological effects such as drowsiness and dizziness, alongside fatigue and a dry mouth.

In the event of a significant overexposure, government health authorities mandate specific emergency actions. Immediate medical help must be sought right away, including contacting a Poison Control Center. Furthermore, regulators state that emergency services (911/equivalent) must be called immediately if the person exhibits severe or life-threatening symptoms, such as a seizure, collapse, trouble breathing, or loss of consciousness. Cardiovascular effects like tachycardia (fast heart rate) or cardiac arrhythmia are considered serious outcomes documented in the overdose context.

No specific antidote is known for fexofenadine overdose. Therefore, treatment is described as being symptomatic and supportive, which may involve standard measures to remove any unabsorbed drug from the gastrointestinal tract. Regulatory guidance also states that hospital observation may be required, including cardiac monitoring and ECG assessment, particularly following a large ingestion. An additional population-specific consideration noted in the labeling is the risk of prolonged elimination in patients with renal impairment.

Therapeutic Uses of Ewofex

What Ewofex Treats: Main Uses and Benefits

The medication is commonly used to provide supportive symptomatic relief across key allergic domains, generally helping to moderate symptoms that create noticeable physiological strain caused by heightened physiological activity. The medicine is commonly used in clinical settings that involve acute or unstable symptom patterns, and is known for its non-sedating profile, which may help patients cope more steadily with symptom fluctuations.


The medication is relevant in conditions characterized by periods of heightened symptoms, including seasonal allergic rhinitis (hay fever), perennial (year-round) rhinitis, and Chronic Idiopathic Urticaria (hives).

Ewofex may assist with easing groups of symptoms that may become intense or disruptive, such as sneezing, runny nose, itchy eyes, and pruritus (severe itching). The medication may assist with maintaining functional stability during symptomatic periods.

“The medication contributes to easing the overall symptom load while supporting a non-sedating experience.”


Quick Fact: Relief for Key Allergic Symptoms

Symptom Domain Typical Manifestations Addressed
Nasal/Ocular Sneezing, runny nose (rhinorrhea), itchy nose, watery eyes, itchy eyes
Cutaneous (Skin) Pruritus (severe itching), wheals (hives), and associated redness
Functional Benefit Non-sedating support to maintain functional stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ewofex?

Eligibility for Ewofex (Fexofenadine) is determined by official regulatory documents and is based on age, physiological status, and known allergies.


Contraindications and Restrictions

Category Eligibility Rule
Absolute Contraindication The medicine is contraindicated in patients with known hypersensitivity to Fexofenadine or any of the inactive ingredients in the specific formulation.
Restricted Use Use must be administered with care in patients with renal impairment (kidney disease) or hepatic impairment (liver disease), due to the risk of altered drug levels. Caution is also required for patients with a history of cardiovascular disease.

Age and Reproductive Status

Population Group Regulatory Status
Adults and Adolescents Generally approved for individuals aged 12 years and over (tablets/capsules). Lower age limits exist for specific formulations (e.g., oral suspension).
Infants Safety and effectiveness have not been established for children below 6 months of age.
Pregnancy/Lactation Not recommended during pregnancy unless clearly necessary, and not recommended for mothers who are breastfeeding.

What should I know about interactions with other medicines?

Ewofex's official regulatory interaction profile is governed by its status as a substrate for specific drug transport proteins (P-glycoprotein and OATP), rather than by hepatic enzyme metabolism, which is officially documented as negligible. No combinations are formally classified as contraindicated due to interaction risk.

Documented Exposure-Modifying Substances

Interaction Type Interacting Substance Official Outcome
Increased Plasma Exposure Erythromycin, Ketoconazole Co-administration leads to a 2 to 3 times increase in Fexofenadine plasma concentration (AUC and Cmax).
Reduced Absorption Antacids (Al/Mg Hydroxide) Bioavailability is decreased due to binding in the gastrointestinal tract.
Reduced Absorption Fruit Juices (Grapefruit, Apple, Orange) Interferes with absorption, resulting in a documented reduction in the amount of medicine absorbed.

Administration Constraints and Conditions

Administration of Fexofenadine must be separated from certain substances and foods according to regulatory guidelines. The medicine should not be taken with fruit juices due to reduced absorption. If administering antacids containing aluminum or magnesium hydroxide, the regulatory labeling advises separating the intake by approximately 2 hours to avoid a reduction in bioavailability.

In studies where Fexofenadine plasma exposure was increased by transporter inhibitors, this increase was formally documented as not associated with effects on the cardiac QT interval or an increase in general adverse reactions, which is a key component of its official interaction summary. The elimination half-life is significantly prolonged in patients with documented renal impairment.

Mechanism of Action

Mechanism of Action: Ewofex Pharmacodynamics

Ewofex exerts its effect through selective inverse agonism at peripheral Histamine H1 Receptors (H1R). The drug binds to the H1R when it is in its inactive conformation, stabilizing this state and thereby preventing the binding and subsequent activation of the receptor by the endogenous mediator, histamine. This action simultaneously suppresses the receptor's basal constitutive activity.

The molecule’s low lipophilicity significantly restricts its penetration of the blood-brain barrier (BBB), ensuring that its mechanistic focus remains concentrated on peripheral pathways located in tissues such as the skin and mucous membranes, minimizing engagement with central nervous system systems.

At the cellular level, the blockade of H1R modifies downstream vasoactive cascades, limiting the histamine-induced increase in vascular permeability and the direct stimulation of sensory nerves. This results in a system-level modulation characterized by reduced fluid extravasation into tissues and a dampening of peripheral nerve signaling.

Dosage and Administration Information

Official Administration Guidelines for Ewofex (Fexofenadine)

Ewofex is administered exclusively via the oral route and is available in formulations including film-coated tablets, oral suspension, and orally disintegrating tablets (ODT). Proper use is defined by standardized dosing schedules and adherence to specific timing restrictions.

The standard adult dosing regimen (for individuals 12 years and older) is 180 mg once daily (qDay) or 60 mg twice daily (BID). This establishes the maximum recommended daily dose at 180 mg. Pediatric patients (ages 6 to 11) typically receive 30 mg twice daily. Dosing differs by age group, and a reduction is indicated for patients with decreased kidney function, where adults receive 60 mg once daily to prevent drug accumulation.

Timing and handling rules are critical for proper absorption. The medicine must be taken with water and strictly not with fruit juices (such as grapefruit, orange, or apple). Furthermore, Ewofex administration must be separated from aluminum- or magnesium-containing antacids by at least two hours. If a dose is missed, the protocol involves skipping the dose and resuming the regular schedule; doubling the dose is not permitted. This defines the standardized, procedural structure for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ewofex


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

The clinical evaluation of Ewofex for Seasonal Allergic Rhinitis (SAR), commonly known as hay fever, relies on research that includes both systematic reviews and meta-analyses that aggregate data from multiple randomized, double-blind, placebo-controlled trials (RCTs). These types of studies represent established research designs used in clinical evaluation. Studies monitored adults and adolescents (age 12 and older), and specific research explored its use in children (aged 6 to 11).

Research used in studies examining symptom intensity or variability explores how outcomes related to physical discomfort were measured. Researchers primarily focused on changes in a Total Symptom Score (TSS), which is used in studies examining patient-reported experiences by combining measures of nasal discomfort (such as sneezing, running, and itching nose) and eye symptoms. Studies contribute to understanding short-term changes and how patients reported their experience across short-term, defined time intervals.


Evidence for Use in Chronic Idiopathic Urticaria (CIU)

Ewofex was evaluated in short- to intermediate-term randomized, placebo-controlled trials for Chronic Idiopathic Urticaria (CIU), a condition characterized by fluctuating or episodic manifestations of recurring hives (wheals) and severe itching (pruritus). Research explored outcomes related to physical discomfort by examining measures related to systemic or functional imbalance. Studies explored changes in patient-reported outcomes describing perceived discomfort, specifically measuring the severity of itching and the number of wheals.


The Non-Sedating Profile in Research Studies

One key area of research involved specialized pharmacodynamic studies and imaging studies (such as PET scans). Researchers monitored objective assessments of activity level, such as psychomotor and cognitive function (like reaction time and attention), as well as subjectively reported drowsiness. Imaging research focusing on the brain H1-receptor occupancy reported minimal to non-detectable levels of occupancy.


Research Gaps and Remaining Uncertainties

The majority of the evidence that Ewofex was evaluated in consists of trials with short-term follow-up durations. Long-term effects are not fully characterized, and there is limited information for long-term outcomes regarding symptom patterns over periods extending beyond a few months. Data for children under six years of age remain insufficient, and comparative evidence is lacking in some areas. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Ewofex (FAQ)


Q: How quickly can a person expect Ewofex to start working?

According to official documentation, the medicine is rapidly absorbed after it is taken by mouth. Studies indicate that the onset of action, or when the effects are documented to commence, is typically within approximately one to three hours.


Q: How long does Ewofex stay in the system after the last use?

Regulatory documents describe the time it takes for the medicine to be eliminated from the body. The terminal elimination half-life of the active ingredient is officially documented to be about 11 to 15 hours in most individuals.


Q: Can Ewofex be used for chronic conditions, or only short-term treatment?

Official information confirms that Ewofex is indicated for managing chronic conditions that may require long-term treatment, such as Chronic Idiopathic Urticaria (hives). The medicine is authorized for chronic conditions, and its use is not limited solely to acute or short-term treatment.


Q: Does Ewofex have a risk of dependence or withdrawal symptoms?

Official safety documents indicate that this medicine does not lead to dependence. Therefore, stopping the medicine has not been reported to cause withdrawal symptoms in patients.


Q: Can Ewofex affect my ability to drive or operate machinery?

Ewofex is classified as non-sedating, meaning it is less likely to cause sleepiness than older antihistamines. However, regulatory documents list dizziness and drowsiness as common side effects that have been reported. This means that some individuals may experience these effects.


Q: What happens if I stop using Ewofex suddenly?

The medicine can be stopped abruptly without needing a tapering schedule. Official information notes that the medicine does not cause withdrawal, though original allergy symptoms may recur.


Q: Does Ewofex require any special monitoring or regular lab tests?

Clinical trial summaries indicate that the frequency of abnormalities in laboratory tests was observed to be similar between those receiving the medicine and those receiving placebo. Official data indicates special ongoing lab monitoring is not typically referenced.


Q: What happens if I use Ewofex for a longer period than originally intended?

Research has looked at the safety profile of the medicine during extended use, with some studies lasting up to 12 months. This research did not indicate any new or unexpected safety risks associated with long-term treatment.


Q: What does the term 'contraindication' mean in relation to Ewofex?

In official drug documents, a contraindication is a specific circumstance or condition that makes the use of the medicine inappropriate or ill-advised. For Ewofex, the medicine is contraindicated if a person has a known hypersensitivity (allergy) to the active ingredient.


Q: Are there any known drug interactions with alcohol while using Ewofex?

Official documents state that the medicine does not appear to increase or potentiate the effects of alcohol.


Q: Why is Ewofex sometimes given with another medicine?

The active ingredient in Ewofex is sometimes combined with another medicine, such as the decongestant pseudoephedrine hydrochloride, in a single fixed-dose formulation. This combination is intended to treat symptoms like nasal congestion alongside allergy symptoms.


Q: Does Ewofex interact with other prescription drugs that cause drowsiness?

Because Ewofex is classified as non-sedating, interactions of a sedative nature are less likely. Regulatory information typically implies caution when combined with other medicines that may cause drowsiness, such as certain types of antidepressants.


Q: Is Ewofex suitable for people who are lactose intolerant?

Official product labeling for certain formulations of the medicine, such as the capsule form, lists lactose as an inactive ingredient (excipient). For those with lactose intolerance, it is noted that specific formulations list lactose as an inactive ingredient.


Q: Does the time of day matter when using Ewofex?

The medicine is prescribed according to a fixed dosing schedule, usually once or twice daily. Following this schedule helps maintain the appropriate level of medicine in the body, establishing the importance of consistent time intervals for use.


Q: What is the general success rate reported in studies for Ewofex?

Clinical trials measure effectiveness by monitoring specific outcomes, rather than stating a single success percentage. Success is measured by the reduction of symptoms captured in the Total Symptom Score (TSS) for allergic rhinitis and a reduction in the severity of itching and number of wheals for hives.


Q: Is there a maximum time limit for using Ewofex?

Official product information does not specify an absolute maximum time limit for continuous use. However, clinical studies have assessed the medicine's safety in continuous use for periods up to 12 months.


Q: Can Ewofex affect mood or cause anxiety?

While not listed among the common side effects, post-marketing experience has documented rare reports of changes such as nervousness and insomnia.


Q: Is Ewofex a long-term maintenance drug?

The medicine is indicated for managing chronic conditions, such as Chronic Idiopathic Urticaria. The medicine’s official indication supports its description as suitable for long-term management.

How should Ewofex be stored and disposed of?

How to Store and Dispose of Ewofex: Official Requirements

Official regulatory guidelines define specific conditions for storing and disposing of this medication (Fexofenadine Hydrochloride).

Storage Conditions:

  • Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
  • Environment: Protect the product from moisture and direct light. It is mandatory to keep the product from freezing.
  • Packaging: Store the medicine in its original container, tightly closed. Orally disintegrating tablets must remain in the blister package until use.
  • Safety: The medication must be kept strictly out of the sight and reach of children.

Disposal Requirements:

Do not dispose of unused or expired medicine in household waste or by flushing it down a sink or toilet (wastewater). Consult a pharmacist for the proper disposal method to help protect the environment and ensure safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ewofex found in:

A-Z Index: